id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0129-0006,FDA,FDA-2006-E-0129,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Eli Lilly and Company,Rule,Certificate Extending Patent Term,2007-05-07T04:00:00Z,2007,5,,,2025-12-10T10:00:06Z,,0,0,0900006480450277
FDA-2006-E-0129-0005,FDA,FDA-2006-E-0129,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-03-12T05:00:00Z,2007,3,,,2025-12-10T02:01:21Z,,0,0,0900006480450276
FDA-2006-E-0129-0004,FDA,FDA-2006-E-0129,Determination of Regulatory Review Period for Purposes of Patent Extension; CYMBALTA,Notice,General Notice,2006-08-03T04:00:00Z,2006,8,2006-08-03T04:00:00Z,,2025-12-10T01:59:40Z,E6-12574,0,0,0900006480450273
FDA-2006-E-0129-0003,FDA,FDA-2006-E-0129,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-21T04:00:00Z,2006,6,,,2025-12-10T01:56:01Z,,0,0,0900006480450272
FDA-2006-E-0129-0002,FDA,FDA-2006-E-0129,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-02-28T05:00:00Z,2006,2,,,2025-12-10T01:54:17Z,,0,0,090000648045026c
FDA-2006-E-0129-0001,FDA,FDA-2006-E-0129,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-01-05T05:00:00Z,2006,1,,,2025-12-10T01:52:21Z,,0,0,0900006480450262